Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 November 2022 | Story Valentino Ndaba
Dr Catherine Namakula
Dr Catherine S. Namakula, Senior Lecturer of Public Law at the UFS and Chairperson of the UN Human Rights Council's Working Group of Experts on People of African Descent.

During the 77th General Assembly of the United Nations (UN), the plight of children of African descent was a main topic of conversation. The conversation was led by Dr Catherine Namakula, Senior Lecturer of Public Law at the University of the Free State (UFS) and Chairperson of the UN Working Group of Experts on People of African Descent (WGEPAD).

On Monday 31 October 2022, in New York, she presented the group’s yearly report, titled ‘Children of African Descent’ to the third committee of the General Assembly. Dr Namakula urged the UN and other stakeholders to avoid using photos of African children and children of African descent in deplorable situations for fundraising and marketing purposes. She stated that "children of African heritage are not synonymous with poverty".

Some of the issues discussed at the meeting included conflicts of law with regard to children of African descent, their disproportionate criminalisation, the intense policing of their families and homes, the racial conditioning of their education, and the use of images of them in degrading circumstances in UN and other stakeholder messaging for marketing and fundraising.

The Working Group recommended the creation of a racial justice index to assess how well states are performing and making progress in improving the well-being of children of African heritage. South Africa was one of the nations that intervened to affirm the report. Among the countries that affirmed other related issues were Russia, Cameroon, China, and Syria.

Dr Namakula also had private meetings with the leaders of the World Council of Churches, UN Women, UNICEF, and other UN agencies to talk about human rights-based approaches to programming aimed at mainstreaming racial justice in their work.

 

African Commission on Human and People’s Rights

In addition, Dr Namakula headed the WGEPAD team to the 73rd regular meeting of the African Commission on Human and People's Rights. She made a statement at the session that brought attention to the opportunities for and necessity of African civil society participation in the work of the Working Group and the UN anti-racism machinery. She made reference to the 'Declaration on People of African Descent' being drafted, to which they may add African perspectives.

Dr Namakula also called attention to the precarious status of victims of modern forms of enslavement, torture, and exploitation in the Middle East and Gulf States, emphasising the important role of civil society in documenting and publicising the tales of vulnerable victims. She emphasised the need for work on the reparations agenda to start right now in order to document Africa's claims and create the necessary institutional and normative frameworks.

She added that efforts are under way to have the UFS Faculty of Law serve as the academic alliance's anchor for the reparations agenda in Africa.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept